Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03703466 |
| Consolidated Lead Sponsor | Eli Lilly and Company |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 72 participants (ACTUAL) |
| Registered Start Date | 2018-11-28 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Peter MacCallum Cancer Centre | Melbourne, Australia | Open Hospital Dossier -> |
| Hospital Universitari Vall d'Hebron | Barcelona, Spain | Open Hospital Dossier -> |
| Hospital Clinico San Carlos | Madrid, Spain | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.